- Nutratopic™ ProAMP for babies and toddlers with atopic dermatitis
Acnisdin™ Calm to alleviate symptoms related to acne medication -
MISSISSAUGA, ON, Jan. 26, 2017 /CNW/ - Crescita Therapeutics Inc. (TSX:CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, today announced that the newly acquired, INTEGA Skin Sciences (INTEGA), a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skincare products has launched the ISDIN® Acnisdin and Nutratopic product lines at Brunet pharmacy chains throughout Québec. The Company anticipates that a number of other categories in the ISDIN product line will be launched by the end of this year in pharmacies across Canada. In addition to the ISDIN products, the INTEGA skincare brands include, Laboratoire Dr Renaud™, Pro-Derm™ and Premiology™.
"We are excited that we have achieved this milestone," said Loic Lefebvre, INTEGA's Vice President, Sales and Marketing. "ISDIN, an international benchmark in skin treatment, provides consumers with a complete range of dermatological solutions and skin care products with the highest quality standard."
ISDIN's focus is to offer a complete range of innovative dermatology solutions to consumers with the highest quality standards and strong clinical evidence. The lead products alleviate symptoms of skin pathologies: dry skin, sun care, atopic dermatitis, women's health, baby skin, acne, oily skin, psoriasis, hygiene and sun damage repair. ISDIN is the market leader in skincare in Spain and was formed in 1975 through a joint venture between Esteve & Puig. ISDIN is well established in Europe, Latin America and Asia with more than 14 brand families and a leading-market position. INTEGA has the exclusive rights to market and sell ISDIN products in Canada.
About Crescita Therapeutics Inc.
Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita's board of directors and management team have demonstrated success in building Crescita's predecessor company, Nuvo Research Inc., including developing multiple drugs that are now approved and commercialized and negotiating multiple licensing transactions. For additional information, please visit www.crescitatherapeutics.com.
*ISDIN® - the trademark is owned by ISDIN S.A. and is being used under license by INTEGA Skin Sciences Inc.
Certain statements in this press release constitute forward-looking information and/or forward-looking statements (collectively, forward-looking statements) within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to Crescita's future governance plans and the expected benefits of the transaction to Crescita's shareholders. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "should" or "plans", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include, but are not limited to, general business and economic uncertainties and adverse market conditions; uncertainties related to Crescita's ability to realize the anticipated benefits of the acquisition; the expected future attributes and success of Crescita and INTEGA; the successful execution of Crescita's and INTEGA's priorities and strategies; the reliability of Nuvo Research's historical financial information as an indicator of Crescita's historical or future results; as well as other risk factors included in Nuvo Research's Management Information Circular dated December 31, 2015 (the Reorganization Circular) and the most recent Crescita Annual Information Form dated March 23, 2016 under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Crescita with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on Crescita's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and none of Crescita, INTEGA or any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Although the forward-looking information contained in this press release is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. All forward-looking statements in this press release are qualified by these cautionary statements. The forward-looking statements contained herein are made as of the date of this press release and, except as required by applicable law, Crescita undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Crescita Therapeutics Inc.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2017/26/c7679.html
For further information: PLEASE CONTACT: Investor Relations, Email: firstname.lastname@example.org